---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-064669"
form_type: "8-K/A"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:39:44.837474+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies finalizes separation with ex-CEO, includes RSU award and board resignation

## Summary
- Ex-CEO R.A. Session II resigned from operating role on Dec 16, 2022; severance agreement finalized March 7, 2023.
- Severance includes salary continuation for 12 months at his base salary as of separation date.
- Also includes COBRA premium payments until Dec 31, 2023 or earlier if new coverage.
- Compensation Committee awarded 251,296 vested RSUs replacing a canceled option of 199,500 shares for 2021 performance bonus.
- Session also resigned from Board on March 2, 2023, not due to any disagreement.

## SEC filing metadata
- accession: 0001193125-23-064669
- form_type: 8-K/A
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523064669/0001193125-23-064669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523064669/d464178d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-064669
- JSON: https://secwatch.observer/filing/0001193125-23-064669.json
- Plain text: https://secwatch.observer/filing/0001193125-23-064669.txt

## Key facts
- Executive change
  R.A. Session II resigned as President and Chief Executive Officer at Taysha Gene Therapies, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On December 16, 2022 (the “ Separation Date ”), R.A. Session II, the former President and Chief Executive Officer of the Company, resigned from his operating role, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523064669/0001193125-23-064669-index.htm
- Executive change
  R.A. Session II resigned as Director at Taysha Gene Therapies, Inc..
  - Action: resigned
  - Role: Director
  source text: On March 2, 2023, Mr. Session notified the Board of his resignation from the Board and all committees thereof effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523064669/0001193125-23-064669-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.